Covid-19 roundup: BeiGene's repurposed BTK inhibitor flops in PhII trial; Philippines suspends AstraZeneca's vaccine after EMA draws link to blood clots
Another repurposed Covid-19 treatment bites the dust.
BeiGene put out word on Thursday that Brukinsa, its mantle cell lymphoma drug, flopped in a Phase II trial with hospitalized Covid-19 patients who need supplemental oxygen.
When compared to a placebo, the small molecule BTK inhibitor missed the co-primary endpoints of respiratory failure-free survival or reduction in the number of days on oxygen, BeiGene said. The trial began last May, and enrolled a total of 67 patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.